Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.

NCT02634008 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.

NCT NCT02634008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02634008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.
Lead sponsor
Kirby Institute
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2016
Completion date
April 30, 2021
Enrollment
83 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, acute